Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...

Researchers studied the efficacy of hydroxyurea at reducing stroke risk in sickle cell anemia, the most common and severe ...